METHODS: Asthma control test (ACT) and sino-nasal outcome test (SNOT-22) scores from fourteen patients with AERD treated at the Brigham and Women’s Hospital AERD Center were retrospectively compared before initiation of mepolizumab and after at least 3 doses of mepolizumab (100mg every four weeks). Wilcoxon signed-rank test was used to compare data.
RESULTS: Treatment with mepolizumab for three or more doses significantly reduced SNOT-22 scores by 17.7 points (SEM 4.9, p = 0.02) and increased ACT scores by 5.1 points (SEM 1.4, p= 0.001). Mepolizumab significantly reduced patient-reported nasal congestion (p<0.03) and improved patient-reported sense of smell (p<0.03).
CONCLUSIONS: In fourteen patients with AERD, IL-5 inhibition with mepolizumab for at least 3 months significantly improved both upper and lower airway symptom scores and notably anosmia and nasal congestion, important quality-of-life measures for AERD patients. The benefit of mepolizumab extends beyond the lower airway and should be examined prospectively in patients with AERD.